Status:
UNKNOWN
Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study
Lead Sponsor:
Assy Nimer
Conditions:
Non-alcoholic Fatty Liver Disease
Cholesterol Ester Storage Disease
Eligibility:
All Genders
18-80 years
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) is a world-wide problem with a global prevalence estimated at 1.5 billion people. It is characterised by significant diversity and phenotypic heterogeneity. M...
Eligibility Criteria
Inclusion
- Age between 18-80 years;
- BMI 25-40;
- Fatty liver disease (bright liver, hepatomegaly by ultrasound (Liver span \> 15 cm mid clavicle line), splenomegaly (\>13 cm) or both.
Exclusion
- Alcohol abuse\>30 gm/day, or \> 70 gram per week;
- Soft drink abuse;
- Drugs known to cause fatty liver;
- Chronic hepatitis (B and C);
- Biliary liver disease;
- Autoimmune hepatitis;
- HIV;
- Genetic/Metabolic liver disease (Wilson, alpha-1 antitrypsin, CF);
- Failure to give informed consent
Key Trial Info
Start Date :
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01791452
Last Update
February 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assy Nimer
Safed, Israel, Israel, 13100